These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35203982)

  • 1. Rasagiline Withdrawal Syndrome in Parkinson's Disease.
    Solla P; Ercoli T; Masala C; Orofino G; Fadda L; Corda DG; Zarbo IR; Meloni M; Sechi E; Bagella CF; Defazio G
    Brain Sci; 2022 Feb; 12(2):. PubMed ID: 35203982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist withdrawal syndrome: implications for patient care.
    Nirenberg MJ
    Drugs Aging; 2013 Aug; 30(8):587-92. PubMed ID: 23686524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of dopaminergic medication withdrawal in Parkinson's disease.
    Koschel J; Ray Chaudhuri K; Tönges L; Thiel M; Raeder V; Jost WH
    J Neural Transm (Vienna); 2022 Sep; 129(9):1169-1178. PubMed ID: 34324057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease.
    Chaudhuri KR; Todorova A; Nirenberg MJ; Parry M; Martin A; Martinez-Martin P; Rizos A; Henriksen T; Jost W; Storch A; Ebersbach G; Reichmann H; Odin P; Antonini A
    Mov Disord Clin Pract; 2015 Jun; 2(2):170-174. PubMed ID: 30713891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.
    Lecht S; Haroutiunian S; Hoffman A; Lazarovici P
    Ther Clin Risk Manag; 2007 Jun; 3(3):467-74. PubMed ID: 18488080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease.
    Oka H; Sengoku R; Nakahara A; Yamazaki M
    Clin Park Relat Disord; 2022; 6():100124. PubMed ID: 34977548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline for the treatment of Parkinson's disease: an update.
    Stocchi F; Fossati C; Torti M
    Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
    Burciu RG; Ofori E; Shukla P; Pasternak O; Chung JW; McFarland NR; Okun MS; Vaillancourt DE
    Hum Brain Mapp; 2016 Aug; 37(8):2894-903. PubMed ID: 27089850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review.
    Garcia X; Mohammad ME; Patel S; Yu XX; Fernandez HH
    Clin Park Relat Disord; 2022; 7():100153. PubMed ID: 35909701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.